Pfizer fronts $250M to nab antisense drug from Akcea/Ionis in up to $1.5B deal
Earlier this year, Pfizer secured early approval of its touted blockbuster — tafamidis — for transthyretin-mediated amyloidosis, a field initially divided between Alnylam and Akcea/Ionis. Now …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
